Optimax Access is a UK-based Health Economics and Outcome Research (HEOR) consultancy company based in the United Kingdom, with an office in the Netherlands as well. We assist our clients in introducing their pharmaceutical and biotech products, and services to major global healthcare markets. We will help you to identify a clear and optimal pathway to success with a comprehensive catalog of services ranging from clinical study design to reimbursement assessment, health economics evidence generation and health technology assessment dossier submission.

Optimax Access has been a preferred business partner for HEOR services for iGES Life Sciences Group (a 40-year-old company based in Germany with multiple offices in Europe) since 2019.

TEAM MEMBERS

A blend of experience from consultancy, industry and academia

Prof Dr Bertram Häussler

Prof Dr Bertram Häussler is head of the IGES group. He is an honorary professor at the Technical University of Berlin for Economics of the Pharmaceutical Industry. His scientific focus is on industrial economics, health economics, health care research, benefit assessment, and drug development.

Dr Amir Ansaripour

Associate Director

Dr. Amir Ansaripour (PharmD., Ph.D.) is a pharmacist and health economist. He has collaborated with most of the top pharma companies by developing cost-effectiveness models for new products for various diseases.
His Ph.D. research focused on cost-effectiveness analyses, modeling, and reimbursement policy analysis. During the past years, he has applied various methods such as questionnaire/survey analysis, Matching-adjusted indirect comparisons (MAICs), data mining on a large claims database, real-world cost analysis, Markov modeling, pharmaceutical pricing, and market access strategy in his projects.

Dr Mehdi Javanbakht

Chief Executive Officer

Mehdi holds a Ph.D. in Health Economics and has over 15+ years of experience in the Health Technology Assessment (HTA) field.  He used to work as an Evidence Review Group (ERG) member for NICE. Mehdi has built over 120 health economic evaluation models from scratch for different diseases (Cancer, diabetes, cardiovascular diseases, Ophthalmology, …) and has published over 130 papers in peer-reviewed journals. He has a strong commercial sense and in-depth knowledge of modeling.

 

Ms Atefeh Mashayekhi

Head of Evidence Synthesis Team

Atefeh is the head of the Evidence Synthesis team at Optimax Access, she worked as an Evidence Synthesis Analyst at NIHR Innovation Observatory for several years. She has a strong background in health economics and Evidence Synthesis and has successfully managed several systematic review projects as part of  NICE HTA submissions for pharmaceutical and medical devices companies. She has also published several Cochrane systematic reviews.

Mr Eoin Moloney

Senior Consultant

Eoin Moloney (MSc) is a senior health economist and evidence synthesis specialist, with 10 years of experience in academia and industry. He has worked across a wide range of clinical disease areas, focussing on the cost-effectiveness and budget-impact of a variety of medical and pharmaceutical interventions. He has a strong track record of publications in high-impact clinical and economic journals and an in-depth understanding of the methods required to demonstrate the cost-effectiveness of new technologies.

Ms Maria Krystallidi

Business Development Manager

Maria is a committed and driven individual with over 17 years of experience in Healthcare, Market access and Commercial roles. Having successfully completed a variety of complex projects in key NHS hospitals and launching new medicines into the market. Maria has extensive experience and knowledge in various therapy areas especially in Oncology, Rheumatoid arthritis, Diabetes, Dermatology, Ophthalmology, Gastroenterology, Bariatrics, and Aesthetics.

Dr Ayaman AL Harrasi

Consultant

Ayaman is a medical doctor (MD), holding a master’s degree in health economics, and has over 12+ years of diversified experience in managing healthcare projects and performing clinical research. She has a strong and in-depth knowledge of modeling and evidence synthesis. Uniquely skilled at converging health care and economics to impact the direction of National health care.

Dr Sajad Emamipour

Consultant

Sajad holds a Ph.D. in Health Economics and he has performed various cost-effectiveness projects in diabetes and cancer, which resulted in several publications. He was previously a member of the evidence review group (ERG) for NICE.

Scientific advisors

Professor Maziar Moradi-Lakeh

Head of Clinical Research Team
Maziar is a Medical Doctor with post-graduate studies in health metric and evaluation. He has been a consultant for several international organizations, governments, and companies. Maziar has contributed to publishing more than 180 papers in peer-reviewed journals.

Jennifer Head – Independent Business Development Manager

Jennifer has worked in the healthcare industry for over 15 years, in a range of commercial and operational roles. She is a passionate advocate for the adoption of innovative solutions within the Global Healthcare Market. Jennifer holds an MSc in Advanced Strategic Marketing and an MBA.

OUR NETWORK

Building successful relationships